What is Theseus Pharmaceuticals Probability of Financial Distress (%)?
Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Theseus Pharmaceuticals's Probability of Financial Distress (%) is 50.00%.
Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.
Competitive Comparison of Theseus Pharmaceuticals's Probability of Financial Distress (%)
For the Biotechnology subindustry, Theseus Pharmaceuticals's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theseus Pharmaceuticals's Probability of Financial Distress (%) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theseus Pharmaceuticals's Probability of Financial Distress (%) distribution charts can be found below:
* The bar in red indicates where Theseus Pharmaceuticals's Probability of Financial Distress (%) falls into.
Theseus Pharmaceuticals Probability of Financial Distress (%) Calculation
Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.
The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:
| LPFD | = | -20.12 * NIMTAAVG | + | 1.60 * TLMTA | - | 7.88 * EXRETAVG | + | 1.55 * SIGMA | - | 0.005 * RSIZE | - | 2.27 * CASHMTA | + | 0.070 * MB | - | 0.09 * PRICE | - | 8.87 |
| = | 0.00 |
The Probability of Financial Distress (%) (PFD) was then obtianed by:
| PFD | = | 1 | / | (1 + e^(-LPFD)) | * | 100% |
| = | 50.00% |
The eight explanatory variables are:
1. NIMTAAVG = Net Income to Market Total Assets
*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.
2. TLMTA = Total liabilities to Market Total Assets
3. CASHMTA = Cash to Market Total Assets
For non-financial companies, CASHMTA is measured as:
4. EXRETAVG = Excess Return compared to the S&P 500
EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.
5. SIGMA = Standard Deviation of Daily Returns
For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).
6. RSIZE = Relative Size
| RSIZE | = | log (Market Cap | / | Total Market Cap of S&P 500 companies) |
7. MB = Market to Adjusted Book Equity Ratio
8. PRICE
PRICE is measured as the log of the stock price, capped at log(15).
Theseus Pharmaceuticals (Theseus Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
245 Main Street, Cambridge, MA, USA, 02142
Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.
Executives
| Orbimed Advisors Llc |
director, 10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Carl L Gordon |
director, 10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Foresite Capital Fund V, L.p. |
10 percent owner |
600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
| Hayden Donald J Jr |
director |
C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
| Bradford D. Dahms |
officer: Chief Financial Officer |
C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472 |
| Timothy P Clackson |
director, officer: President and CEO |
C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Steven H Stein |
director |
1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803 |
| Foresite Capital Opportunity Management V, Llc |
10 percent owner |
900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939 |
| Foresite Capital Opportunity Fund V, L.p. |
10 percent owner |
600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
| Foresite Capital Management V, Llc |
10 percent owner |
900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939 |
| James B. Tananbaum |
10 percent owner |
3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115 |
| William Shakespeare |
officer: See Remarks |
245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142 |
| Rock Springs Capital Master Fund Lp |
10 percent owner |
190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001 |
| Omega Fund Vi Gp Manager, Ltd. |
10 percent owner |
888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199 |
| Orbimed Capital Gp Vii Llc |
10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Theseus Pharmaceuticals (Theseus Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
THRX has been successfully added to your